ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,930.85
      1.09%
      US Tech 100
      20,836.00
      1.31%
      Dow Jones
      42,840.26
      1.18%
      Brent Oil
      72.72
      0.00%
      Bitcoin
      97,376.33
      -0.39%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Marinus Pharmaceuticals Inc (MRNS) Quote

      Marinus Pharmaceuticals Inc

      Marinus Pharmaceuticals Inc (MRNS)

      -3x Mrna
      0.23
      -0.0085
      (-3.56%)
      Closed December 21 4:00PM
      Delayed by 15 minutes
      0.2332
      0.0032
      (1.39%)
      After Hours: 6:56PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      0.2332
      Bid
      0.2303
      Ask
      0.25
      Volume
      1,136,343
      0.2352 Day's Range 0.2472
      0.23 52 Week Range 11.26
      Market Cap
      12.869M
      Previous Close
      0.2385
      Open
      0.241
      Last Trade
      1000
      @
      0.2332
      (formt)
      Last Trade Time
      Financial Volume
      $ 273,329
      VWAP
      0.240534
      Average Volume (3m)
      2,753,301
      Shares Outstanding
      55,185,622
      Dividend Yield
      -
      PE Ratio
      -0.09
      Earnings Per Share (EPS)
      -2.56
      Revenue
      30.99M
      Net Profit
      -141.41M

      About Marinus Pharmaceuticals Inc

      Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.marinuspharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Marinus Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRNS. The last closing price for Marinus Pharmaceuticals was $0.24. Over the last year, Marinus Pharmaceuticals shares have traded in a share price range of $ 0.23 to $ 11.26.

      Marinus Pharmaceuticals currently has 55,185,622 shares outstanding. The market capitalization of Marinus Pharmaceuticals is $13.16 million. Marinus Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.09.

      Ask ADVFN Intelligence (AI)

      MRNS Latest News

      More News

      Form 8-K - Current report

      December 10 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      December 10 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 15 2024
      Edgar (US Regulatory)

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors

      November 14 2024
      Edgar (US Regulatory)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 12 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 12 2024
      Edgar (US Regulatory)

      Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

      ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million...

      November 12 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.0268-10.30769230770.260.2730.2315993460.24696519CS
      4-0.0891-27.64505119450.32230.340.239970120.28221561CS
      12-1.5168-86.67428571431.751.960.2327533010.43244696CS
      26-1.1668-83.34285714291.41.970.2316039080.62447891CS
      52-9.1368-97.51120597659.3711.260.2314704041.74683796CS
      156-10.1968-97.764141898410.4313.150.238088814.01747667CS
      260-1.4368-86.03592814371.6720.040.2310756094.19248562CS

      MRNS - Frequently Asked Questions (FAQ)

      What is the current Marinus Pharmaceuticals share price?
      The current share price of Marinus Pharmaceuticals is $ 0.2332
      How many Marinus Pharmaceuticals shares are in issue?
      Marinus Pharmaceuticals has 55,185,622 shares in issue
      What is the market cap of Marinus Pharmaceuticals?
      The market capitalisation of Marinus Pharmaceuticals is USD 13.16M
      What is the 1 year trading range for Marinus Pharmaceuticals share price?
      Marinus Pharmaceuticals has traded in the range of $ 0.23 to $ 11.26 during the past year
      What is the PE ratio of Marinus Pharmaceuticals?
      The price to earnings ratio of Marinus Pharmaceuticals is -0.09
      What is the cash to sales ratio of Marinus Pharmaceuticals?
      The cash to sales ratio of Marinus Pharmaceuticals is 0.43
      What is the reporting currency for Marinus Pharmaceuticals?
      Marinus Pharmaceuticals reports financial results in USD
      What is the latest annual turnover for Marinus Pharmaceuticals?
      The latest annual turnover of Marinus Pharmaceuticals is USD 30.99M
      What is the latest annual profit for Marinus Pharmaceuticals?
      The latest annual profit of Marinus Pharmaceuticals is USD -141.41M
      What is the registered address of Marinus Pharmaceuticals?
      The registered address for Marinus Pharmaceuticals is 3411 SILVERSIDE ROAD TATNALL BUILDING, #104, WILMINGTON, DELAWARE, 19810
      What is the Marinus Pharmaceuticals website address?
      The website address for Marinus Pharmaceuticals is www.marinuspharma.com
      Which industry sector does Marinus Pharmaceuticals operate in?
      Marinus Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MYSZMy Size Inc
      $ 4.2001
      (211.12%)
      		120.01M
      NVNINVNI Group Ltd
      $ 8.26
      (209.36%)
      		76.64M
      TPICTPI Composites Inc
      $ 2.45
      (100.82%)
      		33.95M
      ICGIntchains Group Ltd
      $ 8.77
      (88.60%)
      		527.61k
      HSDTHelius Medical Technologies Inc
      $ 0.884851
      (84.34%)
      		120.4M
      CYNCYNGN Inc
      $ 0.4603
      (-71.41%)
      		27.91M
      MTEMMolecular Templates Inc
      $ 0.1502
      (-57.09%)
      		8.75M
      PRFXPainReform Ltd
      $ 5.15
      (-53.85%)
      		2.94M
      GALTGalectin Therapeutics Inc
      $ 1.03
      (-48.50%)
      		9.27M
      BCABBioAtla Inc
      $ 0.6923
      (-41.82%)
      		6.25M
      EDBLEdible Garden AG Inc
      $ 0.24
      (65.06%)
      		354.33M
      NVDANVIDIA Corporation
      $ 134.70
      (3.08%)
      		310.19M
      APTOAptose Biosciences Inc
      $ 0.28
      (64.51%)
      		306.25M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.606999
      (6.49%)
      		293.22M
      PLTRPalantir Technologies Inc
      $ 80.55
      (8.54%)
      		281.23M

      MRNS Discussion

      View Posts
      NASDAQ2020 NASDAQ2020 3 weeks ago
      That it is !!!!
      👍️0
      glenn1919 glenn1919 4 months ago
      MNRS................................https://stockcharts.com/h-sc/ui?s=MNRS&p=W&b=5&g=0&id=p86431144783
      👍️0
      Money hunt Money hunt 8 months ago
      1.27 Wall gong to get busted down Watch out shorties,
      👍️0
      Money hunt Money hunt 8 months ago
      MRNS Has got bulls with balls dude
      👍️0
      Money hunt Money hunt 8 months ago
      Watch out shorties We the Next PALI So you can all burn in hell where you belong
      👍️0
      ErnieBilco ErnieBilco 8 months ago
      MRSN under $2
      👍️0
      Awl416 Awl416 8 months ago
      Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
      👍️0
      Monksdream Monksdream 9 months ago
      MRNS under $10
      👍️0
      oldstocks oldstocks 10 months ago
      Drug Companies making Epilepsy medication
      MRNS $10.08
      CERE $43.16
      STOK $4.98
      UCBJF $102.00
      SNY $45.63
      PFE $27.00
      OTSUK $18.36
      RespireRx Pharmaceuticals Ticker: RSPI
      Is working on Revolutionary New Hope:
      KRM-II-81 Drug-Resistant Epilepsy Patients

      Don't take my word for it, look at the links that talk about it.

      Link found on National Library of Medicine
      The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

      https://pubmed.ncbi.nlm.nih.gov/35041859/

      https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/

      National Institutes of Health
      A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
      KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/
      👍️0
      matt51 matt51 2 years ago
      Has Marinus enrolled the eighty-second patient for the phase 3 RSE trial?
      👍️0
      Cosa Cosa 2 years ago
      Did you add more here? This recovered well from the bottom. I was putting all into ARDX and AUPH, didn't add any here.
      👍️0
      Cosa Cosa 2 years ago
      Thanks, I will look.
      👍️0
      Ganz Ganz 2 years ago
      Ha, our time is coming for MRNS Cosa, also check out MIRM
      👍️0
      Cosa Cosa 3 years ago
      Good thing that's all you had lol! This is definitely not volatile enough to trade. And a good investment?...Time will tell.
      👍️0
      missile_systems missile_systems 3 years ago
      Yeah Buddy…. Hoping for good news.
      Just stumbled upon this on Friday afternoon.
      Only had enough powder to grab a hundred shares.
      Please don’t laugh too hard….lol.

      Anyway, it’s weird that there haven’t been any posts on this board since before last Christmas!

      Peace
      mis
      👍️0
      Cosa Cosa 3 years ago
      let's see what happens Monday...
      👍️0
      Cosa Cosa 3 years ago
      Everything I have is Red, not a single green. lol!
      👍️0
      flsh56 flsh56 3 years ago
      ... don't look now, it's been six months since this happened, but mrns just decently broke through their 50dma
      👍️0
      Ganz Ganz 3 years ago
      Cosa, you there ?
      👍️0
      Ganz Ganz 4 years ago
      Cosa, good to see you on this board, MRNS - like AUPH - is primed to pop.
      👍️0
      whytestocks whytestocks 4 years ago
      JUST IN: $MRNS 3 Biotech Stocks That Surged Last Week

      Dozens of healthcare stocks grew by double-digit percentages last week, and shares of these three drugmakers rose further than nearly all of their peers. Clinical trial results, coronavirus vaccine progress, and a buyout were the major factors that turned these biotech stocks into big gainers la...

      Read the whole news MRNS - 3 Biotech Stocks That Surged Last Week
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $MRNS Video Chart 09-15-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      Cosa Cosa 4 years ago
      Woohoo! Huge upswing
      👍️0
      whytestocks whytestocks 4 years ago
      NEWS: $MRNS Top Penny Stocks To Buy, Sell Or Hold? Analysts Weigh In On These 4

      4 Penny Stocks To Buy Right Now According To Analysts Whether you buy penny stocks because of analysts or simply use ratings in your overall strategy, it helps to get a full lay of the land. What I mean by this is that most retail traders will look at a few facets of certain companies. They...

      Find out more MRNS - Top Penny Stocks To Buy, Sell Or Hold? Analysts Weigh In On These 4
      👍️0
      whytestocks whytestocks 4 years ago
      Breaking News: $MRNS Nasdaq Rises Despite Nikola Hit; Marinus Soars

      Many investors have been worried about the Nasdaq Composite (NASDAQINDEX: ^IXIC) lately. The index has taken a leadership role during 2020's huge rebound from the coronavirus bear market, but its steep decline in early September made some believe that the best of times for the Nasdaq were no...

      Got this from MRNS - Nasdaq Rises Despite Nikola Hit; Marinus Soars
      👍️0
      UFO UFO 4 years ago
      Just announced phase #3 results rocked. Stock is on the way to $10+.

      UFO
      👍️0
      MKthe great MKthe great 4 years ago
      ??????
      👍️0
      UFO UFO 4 years ago
      Go Marinus!

      UFO
      👍️0
      whytestocks whytestocks 4 years ago
      News: $MRNS Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

      Clinical trials remain on track, with Refractory Status Epilepticus (SE) trial expected to begin enrollment shortly CDKL5 deficiency disorder (CDD) pivotal topline results on track for Q3; Conference call to be scheduled to discuss CDD data release and business update Organiz...

      Find out more MRNS - Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
      👍️0
      UFO UFO 5 years ago
      On the move!

      UFO
      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $MRNS Video Chart 05-29-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      UFO UFO 5 years ago
      Go Marinus!

      UFO
      👍️0
      agribusiness72 agribusiness72 5 years ago
      minor pump from yahoo finance. will see how low it drops before buying in.
      👍️0
      UFO UFO 5 years ago
      Looks like a move is on.

      UFO
      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $MRNS Video Chart 03-16-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $MRNS Video Chart 02-20-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $MRNS Video Chart 02-18-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      nuclear profitz nuclear profitz 5 years ago
      breaking out.
      👍️0
      Cosa Cosa 5 years ago
      Good points. I'm sure they will find something it works on. The science behind it is still unknown. The good thing about ganaxolone is it has very little side effects. So if one of the phases does well it is a gold mine! I traded on the momentum and will get back in a little cheaper and a lot less shares so there is no stress lol.

      I like Epidiolex seems to be gaining momentum since it's FDA approval last year. It targets the same symptoms of ganaxolone with very little side effects also.

      Good luck to you!
      👍️0
      UFO UFO 5 years ago
      All I've seen them have an issue with is one trial. Now they have a treasure chest full of money and some aggressive money manager backing. IMHO, this would be the WORST time to bail out on the company. Did you read the corporate outlook that was released today? They have about 4 trials in progress and the ability to fund them all. You think ganaxolone is going to fail on all of them? I like the odds here. At the least I think we'll see a rally into the Phase 3 results that we'll see later this year. Go Marinus!

      UFO
      👍️0
      Cosa Cosa 5 years ago
      The more I research this stock the more I do not like. Ganaxolone doesnt look like it is doing well in clinical trials.
      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $MRNS Video Chart 12-24-2019 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      Cosa Cosa 5 years ago
      Could see that big move up sometime next month

      https://www.nasdaq.com/articles/implied-volatility-surging-for-marinus-pharmaceuticals-mrns-stock-options-2019-12-23
      👍️0
      UFO UFO 5 years ago
      Agreed. I've never seen a stock rally like this as a "major" financing is going on! Somebody knows something...just saying...

      UFO
      👍️0
      Cosa Cosa 5 years ago
      Possible 10 bagger with a short squeeze.
      👍️0
      UFO UFO 5 years ago
      Go Marinus!

      UFO
      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $MRNS Video Chart 12-20-2019 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      UFO UFO 5 years ago
      If they get GREAT results from their phase 3, this is a $40 - $50 stock!

      UFO
      👍️0
      Cosa Cosa 5 years ago
      If they pass a phase 3 this is going to $10 - $16
      👍️0
      Cosa Cosa 5 years ago
      I'm late to the party. Just got in, more room to grow
      👍️0

      Your Recent History

      NASDAQ
      MRNS
      Marinus Pharmaceuticals
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads